Challenges and Strategies in an Evolving
Chronic Lymphocytic Leukemia (CLL) Treatment Paradigm:
What Does Managed Care Need to Know
A continuing medical education activity sponsored by NAMCP and AAMCN.
This activity is an archive from the
live session at the 2017 Fall Forum. If you participated in the live
session, you are not eligible for continuing education credits from
This activity is valid from April 30, 2018 to April 30, 2019
Instructions for CME/CNE: Complete the pre-test, listen to the audio
and view the slides, complete the post test, complete the evaluation
form and hit submit. You will be asked to enter your name and email
address on the pre-test, evaluation and post-test. If you close your
internet browser without completing the post test, you will have ONE
more opportunity to complete. A score of 70% must be achieved on the
post test to receive continuing education credits. If you do not
pass the post test after two attempts, you will not be eligible to
try again. Once you complete the evaluation form and score 70% or
higher on your post test, you will automatically be given your
To print or save your certificate, you will need to click on the
“download” button and either print or save.
Audience: This activity is intended for
healthcare professionals practicing in managed care environments.
This presentation is supported by
educational grants from
AbbVie and Pharmacyclics
Chronic lymphocytic leukemia (CLL) is a cancer of the blood and bone
marrow and is the most common type of leukemia in adults. Patients
with CLL are often diagnosed when they are asymptomatic; therefore,
knowing when to initiate treatment may pose a challenge to
clinicians. Furthermore, patients with CLL have impaired immune
systems and multiple comorbidities, which can complicate management
and impact treatment decisions. Fortunately for patients with CLL,
several new treatments, including targeted therapies, have recently
become available, giving clinicians many new options to improve
Upon Completion of this
activity, participants will be able to:
Describe the role of diagnostic
testing, staging, biomarkers and prognostic assessment tools in
CLL pathway development and their use for informing treatment
Examine clinical data on newer
therapies for patients with CLL who have received at least one
Integrate current and new safety and
efficacy data evaluating recently approved agents for CLL into
clinical pathways taking into consideration cytogenetic
abnormalities, patient age, performance status, and
Apply methods to enable optimal cost
management of newer therapies to be realized by multiple CLL
stakeholders including managed care organizations
Analyze the role of BCL-2 inhibitors
in the management of patients with CLL
||Michael Keating, MB, BS
Department of Leukemia
Division of Cancer Medicine
MD Anderson Cancer Center
serves as a consultant to Celgene and Hoffman LaRoche.
His presentation has been peer reviewed for any bias.
MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships
Jacqueline Cole, RN, MS, CMCN has no relevant financial
relationships to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity.
Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is
accredited by the Accreditation Council for Continuing Medical
Education to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category I creditsTM.
The American Association of Managed Care Nurses is accredited as a
provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission
Nurses who complete this activity and achieve a passing score will
receive 1 hour in continuing
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
supported by educational grants from
AbbVie and Pharmacyclics
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
Click Here To Continue